The Fed Hiked and the Long End Fell.

This week's five

1. 01

   GNRC, view score card · Generac Holdings · Industrials / Electrical Equipment

   Move before publication

   +14.2%

   Next date

   Oct 29

   Generac disclosed a long term agreement to supply backup generators to Amazon data centers, with roughly 2.4 billion dollars of deliveries scheduled for 2027 and 2028 against 4.44 billion dollars of trailing twelve month revenue for the whole company. The stock rose 18.3 percent on September 17 on 6.7 times normal volume and held the gap the next day. It still trades 30 percent below its 52 week high at about 20 times forward earnings, which is the rare case where a large move did not leave an expensive stock.

   The catalyst. On September 16, 2026 Generac entered a transaction agreement with Amazon and filed it the same day. Initial deliveries of backup generators for Amazon data centers are expected to total 2.4 billion dollars in 2027 and 2028, with warrant vesting contingent on aggregate gross payments of up to 8 billion dollars. Amazon received a warrant for 1,693,745 shares at an exercise price of 200.9266 dollars, of which 307,954 vested on issuance. The stock rose 18.3 percent on September 17 on 6.7 times average volume and held the gap the following session. U.S. Securities and Exchange Commission, September 16, 2026

   Why it made the five. Generac has spent years trying to stop being a company whose revenue depends on storms, and this is that transition arriving in one document. The initial delivery figure alone is more than half of what the whole company sold in the last twelve months, and it is contracted rather than forecast. It also lands in the physically constrained part of the artificial intelligence build out: data centers need backup power before they need anything else, and that capacity has to be manufactured. Of everything in the screen this week, it is the only catalyst that is a signed order rather than a mood, an upgrade or a conference slide.

   What to watch next. Oct 29: Third quarter results, expected late October though the date is not yet announced, the first report where data center backlog and 2027 capacity get quantified Confirms the thesis: Management raises the data center revenue outlook and puts a number on large megawatt manufacturing capacity for 2027 Breaks it: The Amazon deliveries are described as replacing other commercial demand rather than adding to it, or capacity spending eats the margin

   The case against it. The customer is now also a shareholder, so the reward for delivering is partly paid in dilution: Amazon holds a warrant for up to 1,693,745 shares at 200.9266 dollars, roughly 2.87 percent of the 59.06 million shares outstanding. Revenue does not begin until 2027, leaving five quarters in which nothing about the thesis can be confirmed by results. One buyer now anchors the growth case and holds the leverage that comes with it. The hurricane season has been quiet, so the residential business is carrying nothing while a reader waits, and chief executive Aaron Jagdfeld sold 5,000 shares on September 1 under a scheduled plan.

   Weekly move (before publication): +14.2%

   Every GNRC appearance →Track this pick on the Scoreboard →Size a position in it →

2. 02

   MPC, view score card · Marathon Petroleum Corporation · Energy / Refining and Marketing

   Next date

   Nov 3

   Crude fell while refined product margins did not, which is the entire refining trade in one line. West Texas Intermediate slipped about 0.5 percent on the week to 99.53 dollars while diesel cracks sat at record levels, and Marathon rose 8.27 percent to close at an all time high. The stock trades at 7.5 times forward earnings, which looks cheap until you notice trailing earnings are 14.7 times and the gap between the two is the crack spread windfall being extrapolated.

   The catalyst. Crude eased while refined product margins did not. West Texas Intermediate fell about 0.5 percent on the week to 99.53 dollars a barrel as Saudi Arabia signalled it could restore roughly half of the damaged East to West pipeline capacity within days, while diesel crack spreads held at record levels. Marathon closed at an all time high of 424.89 dollars on September 18, its sixth consecutive weekly gain, verified from Friday close to Friday close. CNBC, September 17, 2026

   Why it made the five. A refiner does not sell oil, it sells the difference between oil and the fuel made from it, which is why this is the one name in the issue that improves when crude falls. Marathon's realized refining margin ran at 36.33 dollars a barrel last quarter against 17.58 a year earlier, and the reason is supply rather than demand: drone strikes have removed more than 2.8 million barrels a day of Russian refining capacity, on top of permanent European and North American closures that lowered the floor before any of this started. It is also the only pick that would benefit from the energy leg that would hurt the other four.

   What to watch next. Nov 3: Third quarter results, confirmed for November 3, where the realized refining margin per barrel is the only number that matters Confirms the thesis: Realized refining margin holds near the 36 dollar a barrel level reported last quarter Breaks it: Margins compress as Saudi pipeline capacity returns and idled refining restarts, which has been flagged as a within weeks event

   The case against it. This is the most extended name in the issue. It closed at 99.3 percent of its 52 week high after six consecutive weekly gains, above the average published analyst valuation of 370.17 dollars. It trades at 7.5 times forward earnings against 14.7 times trailing, and that gap is not cheapness, it is a windfall being extrapolated. Energy was also a falling sector this week at negative 0.95 percent, so the pick fights its own sector label. Saudi Arabia has signalled it can restore roughly half the damaged East to West pipeline capacity within days and full operations within about six weeks, and product cracks would begin narrowing before that work finishes.

   Every MPC appearance →Track this pick on the Scoreboard →Size a position in it →

3. 03

   KR, view score card · The Kroger Co. · Consumer Staples / Food Retail

   Next date

   Dec 3

   Kroger cut its full year identical sales outlook to a range of 0.2 to 0.8 percent from 1.0 to 2.0 percent on September 11, and reaffirmed adjusted earnings of 5.10 to 5.30 dollars anyway. The market paid for the margin rather than punishing the top line, sending the stock up 5.36 percent on the week. At 11.4 times forward earnings with a 2.6 percent dividend, the price says very little growth is expected, which is the honest reason to look at it.

   The catalyst. On September 11, 2026 Kroger reported second quarter identical sales excluding fuel up 0.2 percent and adjusted earnings of 1.09 dollars a share, up 5 percent. It cut full year identical sales guidance to a range of 0.2 to 0.8 percent from 1.0 to 2.0 percent, citing pharmacy headwinds and cautious consumer spending, while reaffirming adjusted earnings of 5.10 to 5.30 dollars and adjusted FIFO operating profit of 5.0 to 5.2 billion dollars. Adjusted eCommerce sales rose 20 percent and retail media 24 percent. The Kroger Co., September 11, 2026

   Why it made the five. A company lowered what it expects to sell, kept what it expects to earn, and the stock rose 5 percent. That tells you what this market is currently paying for, and it is margin control rather than growth. Two businesses are doing the work, a digital operation growing 20 percent and a retail media arm growing 24 percent, both of which carry structurally better economics than selling groceries. At 11.4 times forward earnings with a 2.6 percent dividend, almost none of that is in the price, which is the honest reason to look at it rather than the move itself.

   What to watch next. Dec 3: Third quarter results, expected early December, the first read on whether the profit guidance survives a cut sales line Confirms the thesis: Identical sales land in the upper half of the reduced range while gross margin holds Breaks it: Another identical sales cut, or margin giving back what the sales line already gave up

   The case against it. Holding profit guidance while cutting sales guidance works right up until costs move, and this is a business whose costs are moving: diesel is a delivery charge on every item in the store and it rose 24.1 percent in a single month in the August producer price data. The company named cautious consumer spending itself as a reason for the cut, which is not a problem margin discipline can fix. The stock reached 62.25 dollars on September 15 and closed the week at 60.00, giving back more than a third of its gain before Friday was out.

   Every KR appearance →Track this pick on the Scoreboard →Size a position in it →

4. 04

   ZS, view score card · Zscaler, Inc. · Technology / Cybersecurity

   Move before publication

   +20.7%

   Next date

   Nov 24

   Security software rerated as a group on September 14 after weekend warnings from frontier artificial intelligence lab chief executives about autonomous agent risk, on the logic that a more dangerous threat environment raises security budgets whatever else happens. Zscaler rose 16.5 percent that session on 2.7 times normal volume and finished the week up 20.69 percent. It trades at 40 times forward earnings and 9.6 times sales, is still loss making on a reported basis, and even after this week sits 41 percent below its 52 week high.

   The catalyst. Security software repriced as a group on September 14, 2026 after weekend essays from frontier artificial intelligence lab chief executives warned that autonomous agent swarms could cause damage running to hundreds of billions of dollars, on the reasoning that a more dangerous threat environment raises security budgets regardless of adoption speed. Zscaler rose 16.5 percent that session on 2.7 times average volume, with CrowdStrike and Palo Alto Networks moving alongside it, and finished the week up 20.69 percent at 197.31 dollars. 24/7 Wall St., September 14, 2026

   Why it made the five. Of the names that repriced together on September 14, this is the one with something underneath the story. Zscaler reported on September 3 with revenue of 898 million dollars against an 877 million dollar consensus, up 25 percent, and guided fiscal 2027 revenue to 3.91 to 3.94 billion dollars with earnings above consensus. So the sector received a narrative and this company already had the numbers. It also held its gain into Friday while CrowdStrike and Palo Alto Networks each gave back roughly 3 percent from their midweek highs, which is what separated it from the group.

   What to watch next. Nov 24: First quarter fiscal 2027 results, expected late November, the first test of whether the spending narrative shows up in billings Confirms the thesis: Billings growth accelerates above the 25 percent revenue growth rate reported for fiscal 2026 Breaks it: Billings decelerate, which would mark this week as a sentiment move with nothing underneath it

   The case against it. Nothing about the business changed on September 14. A 16.5 percent single session move on an essay is multiple expansion, and multiple expansion reverses without warning: my own record includes a software re-rating in Issue No. 10 that I named as a risk and that duly handed itself back within two weeks. The stock trades at 40 times forward earnings and 9.6 times sales and still loses money on a reported basis, with the net loss widening 52 percent in fiscal 2026. Chief financial officer Kevin Rubin sold 5,957 shares on September 16, two days after the move, at an average of 192.76 dollars.

   Weekly move (before publication): +20.7%

   Every ZS appearance →Track this pick on the Scoreboard →Size a position in it →

5. 05

   NTRA, view score card · Natera, Inc. · Health Care / Diagnostics

   Move before publication

   +13.3%

   Next date

   Nov 5

   Natera presented the largest molecular residual disease dataset ever shown in lung cancer at the World Conference on Lung Cancer, covering 1,129 patients with resected stage 1 to 3 non small cell lung cancer, where test positive patients carried roughly five times the risk of recurrence or death. The stock rose 13.26 percent and closed the week at a record. It also trades at about 19.6 times sales and does not yet make money, so the evidence is clinical and the price is aspirational.

   The catalyst. At the IASLC 2026 World Conference on Lung Cancer, Natera presented the largest molecular residual disease dataset ever shown in the disease: 1,129 patients with resected stage 1 to 3 non small cell lung cancer followed from 2016 to 2025. Patients whose Signatera test was positive shortly after surgery carried roughly five times the risk of recurrence or death during surveillance. The company published the release on September 18, 2026 and the stock closed at a record 369.39 dollars on 2.7 times average volume. Natera, Inc., September 18, 2026

   Why it made the five. Evidence at this scale is how a test moves from useful to expected. The clinical problem it addresses is concrete: after surgery a physician has to decide whether to give chemotherapy to a patient who may already be cured, and a blood test that separates five times risk from baseline risk changes that conversation. Revenue is already growing 37.8 percent to 2.71 billion dollars, so the commercial engine exists rather than being hoped for. It was also the only Health Care name in the screen with a dated, company specific catalyst inside the window.

   What to watch next. Nov 5: Third quarter results, expected early November, where Signatera test volume is the number that converts clinical data into revenue Confirms the thesis: Sequential volume growth holds near the 34,000 unit record pace set earlier this year Breaks it: Volume growth decelerates, or payers decline to extend reimbursement from prognosis into treatment decisions

   The case against it. This is the widest gap between evidence and price in the issue, which is why it goes last. Natera is not profitable, reporting a net loss of 192.35 million dollars, and trades at roughly 19.6 times sales at 99.9 percent of its 52 week high. Prognostic data is also not a reimbursement decision: showing that a test predicts recurrence is easier than showing that acting on the result improves survival, and payers fund the second. Co-founder Jonathan Sheena disposed of 6,000 shares on September 15 at 350.07 dollars under a scheduled plan.

   Weekly move (before publication): +13.3%

   Every NTRA appearance →Track this pick on the Scoreboard →Size a position in it →